Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 14, 2014 - Issue 1
Submit an article Journal homepage
510
Views
8
CrossRef citations to date
0
Altmetric
Reviews

Pharmacotherapy of generalized anxiety disorder: focus and update on pregabalin

Charlotte BothDepartment of Pharmacology and Clinical Pharmacology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany
,
Georg KojdaDepartment of Pharmacology and Clinical Pharmacology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany
&
Christian Lange-AsschenfeldtDepartment of Psychiatry and Psychotherapy, Medical Faculty, Heinrich Heine University, Düsseldorf, GermanyCorrespondence[email protected] [email protected]
Pages 29-38 | Published online: 22 Nov 2013

References

  • Wittchen HU, Jacobi F, Rehm J et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 21(9), 655–679 (2011).
  • Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62(6), 593–602 (2005).
  • Hoge EA, Ivkovic A, Fricchione GL. Generalized anxiety disorder: diagnosis and treatment. BMJ 345, e7500 (2012).
  • Altamura AC, Dell’osso B, D’Urso N, Russo M, Fumagalli S, Mundo E. Duration of untreated illness as a predictor of treatment response and clinical course in generalized anxiety disorder. CNS Spectr. 13(5), 415–422 (2008).
  • Davidson JR, Feltner DE, Dugar A. Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs. Prim. Care Companion. J. Clin. Psychiatry 12(2) (2010).
  • Bandelow B, Charimo TA, Wedekind D, Broocks A, Hajak G, Ruther E. Early traumatic life events, parental rearing styles, family history of mental disorders, and birth risk factors in patients with social anxiety disorder. Eur. Arch. Psychiatry Clin. Neurosci 254(6), 397–405 (2004).
  • Kim MJ, Loucks RA, Palmer AL et al. The structural and functional connectivity of the amygdala: from normal emotion to pathological anxiety. Behav. Brain Res. 223(2), 403–410 (2011).
  • Andreescu C, Gross JJ, Lenze E et al. Altered cerebral blood flow patterns associated with pathologic worry in the elderly. Depress. Anxiety 28(3), 202–209 (2011).
  • Charney DS. Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatr. Scand. Suppl. (417), 38–50 (2003).
  • Germine M, Goddard AW, Woods SW, Charney DS, Heninger GR. Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder. Biol. Psychiatry 32(5), 457–461 (1992).
  • Lohoff FW, Narasimhan S, Rickels K. Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics. J. 13(5), 464–469 (2012).
  • Vreeburg SA, Zitman FG, van PJ et al. Salivary cortisol levels in persons with and without different anxiety disorders. Psychosom. Med. 72(4), 340–347 (2010).
  • Molina E, Cervilla J, Rivera M et al. Polymorphic variation at the serotonin 1-A receptor gene is associated with comorbid depression and generalized anxiety. Psychiatr. Genet. 21(4), 195–201 (2011).
  • Bereza BG, Machado M, Ravindran AV, Einarson TR. Evidence-based review of clinical outcomes of guideline-recommended pharmacotherapies for generalized anxiety disorder. Can. J. Psychiatry 57(8), 470–478 (2012).
  • Bandelow B, Sher L, Bunevicius R et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int. J. Psychiatry Clin. Pract. 16(2), 77–84 (2012).
  • Baldwin DS, Waldman S, Allgulander C. Evidence-based pharmacological treatment of generalized anxiety disorder. Int. J. Neuropsychopharmacol. 14(5), 697–710 (2011).
  • Stein DJ, Picarel-Blanchot F, Kennedy SH. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. Hum. Psychopharmacol. 28(2), 151–159 (2013).
  • Stein DJ, Ahokas A, Albarran C, Olivier V, Allgulander C. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J. Clin. Psychiatry 73(7), 1002–1008 (2012).
  • Martinotti G, Sepede G, Gambi F et al. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. J. Clin. Psychopharmacol. 32(4), 487–491 (2012).
  • Bossini L, Casolaro I, Koukouna D, Cecchini F, Fagiolini A. Off-label uses of trazodone: a review. Expert Opin. Pharmacother. 13(12), 1707–1717 (2012).
  • Nemeroff CB. The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol. Bull. 37(4), 133–146 (2003).
  • Rynn MA , Brawman-Mintzer O. Generalized anxiety disorder: acute and chronic treatment. CNS Spectr. 9(10), 716–723 (2004).
  • Bandelow B, Sher L, Bunevicius R et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int. J. Psychiatry Clin. Pract. 16(2), 77–84 (2012).
  • Huh J, Goebert D, Takeshita J, Lu BY, Kang M. Treatment of generalized anxiety disorder: a comprehensive review of the literature for psychopharmacologic alternatives to newer antidepressants and benzodiazepines. Prim. Care Companion. CNS Disord. 13(2), (2011).
  • Zahreddine N, Richa S. Non-antidepressant treatment of generalized anxiety disorder. Curr. Clin. Pharmacol. (2013) ( Epub ahead of print).
  • Lader M , Scotto JC. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology (Berl) 139(4), 402–406 (1998).
  • Buoli M, Caldiroli A, Caletti E, Paoli RA, Altamura AC. New approaches to the pharmacological management of generalized anxiety disorder. Expert Opin. Pharmacother. 14(2), 175–184 (2013).
  • Aikins DE, Craske MG. Cognitive theories of generalized anxiety disorder. Psychiatr. Clin. North Am. 24(1), 57–74, vi (2001).
  • Hofmann SG, Smits JA. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J. Clin. Psychiatry 69(4), 621–632 (2008).
  • Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet 368(9553), 2156–2166 (2006).
  • Bystritsky A, Kaplan JT, Feusner JD et al. A preliminary study of fMRI-guided rTMS in the treatment of generalized anxiety disorder. J. Clin. Psychiatry 69(7), 1092–1098 (2008).
  • Bystritsky A, Kerwin LE, Feusner JD. A preliminary study of fMRI-guided rTMS in the treatment of generalized anxiety disorder: 6-month follow-up. J. Clin. Psychiatry 70(3), 431–432 (2009).
  • Bandelow B, Wedekind D, Leon T. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev. Neurother. 7(7), 769–781 (2007).
  • Di Nicola M, Martinotti G, Tedeschi D et al. Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome. Hum. Psychopharmacol. 25(3), 268–275 (2010).
  • Martinotti G, Di NM, Frustaci A et al. Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial. Addiction 105(2), 288–299 (2010).
  • Oulis P , Konstantakopoulos G. Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence. Expert Opin. Investig. Drugs 21(7), 1019–1029 (2012).
  • Samuel M, Zimovetz EA, Gabriel Z, Beard SM. Efficacy and safety of treatments for refractory generalized anxiety disorder: a systematic review. Int. Clin. Psychopharmacol. 26(2), 63–68 (2011).
  • Bandelow B, Zohar J, Hollander E et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J. Biol. Psychiatry 9(4), 248–312 (2008).
  • Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol. Sci. 28(2), 75–82 (2007).
  • Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin. Ther. 29(1), 26–48 (2007).
  • Stahl SM. Mechanism of action of alpha2delta ligands: voltage sensitive calcium channel (VSCC) modulators. J. Clin. Psychiatry 65(8), 1033–1034 (2004).
  • Hadley SJ, Mandel FS, Schweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J. Psychopharmacol. 26(4), 461–470 (2012).
  • Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin. Pharmacokinet. 49(10), 661–669 (2010).
  • Ohman I, Vitols S, Tomson T. Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy? Epilepsia 46(10), 1621–1624 (2005).
  • Tomson T , Battino D. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. Clin. Pharmacokinet. 46(3), 209–219 (2007).
  • Dworkin RH, Corbin AE, Young JP Jr et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 60(8), 1274–1283 (2003).
  • Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J. Clin. Pharmacol. 43(3), 277–283 (2003).
  • Bech P. Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry 40(4), 163–168 (2007).
  • Feltner DE, Crockatt JG, Dubovsky SJ et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J. Clin. Psychopharmacol. 23(3), 240–249 (2003).
  • Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J. Clin. Psychiatry 67(5), 771–782 (2006).
  • Kasper S, Herman B, Nivoli G et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int. Clin. Psychopharmacol. 24(2), 87–96 (2009).
  • Feltner D, Wittchen HU, Kavoussi R, Brock J, Baldinetti F, Pande AC. Long-term efficacy of pregabalin in generalized anxiety disorder. Int. Clin. Psychopharmacol. 23(1), 18–28 (2008).
  • Greist JH, Liu-Dumaw M, Schweizer E, Feltner D. Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study. Int. Clin. Psychopharmacol. 26(5), 243–251 (2011).
  • Rickels K, Pollack MH, Feltner DE et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch. Gen. Psychiatry 62(9), 1022–1030 (2005).
  • Pande AC, Crockatt JG, Feltner DE et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am. J. Psychiatry 160(3), 533–540 (2003).
  • Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ 342, d1199 (2011).
  • Stein DJ, Baldwin DS, Baldinetti F, Mandel F. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur. Neuropsychopharmacol. 18(6), 422–430 (2008).
  • Lydiard RB, Rickels K, Herman B, Feltner DE. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int. J. Neuropsychopharmacol. 13(2), 229–241 (2010).
  • Rickels K, Shiovitz TM, Ramey TS, Weaver JJ, Knapp LE, Miceli JJ. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int. Clin. Psychopharmacol. 27(3), 142–150 (2012).
  • Cabrera J, Emir B, Dills D, Murphy TK, Whalen E, Clair A. Characterizing and understanding body weight patterns in patients treated with pregabalin. Curr. Med. Res. Opin. 28(6), 1027–1037 (2012).
  • Ogawa S, Satoh J, Arakawa A, Yoshiyama T, Suzuki M. Pregabalin treatment for peripheral neuropathic pain: a review of safety data from randomized controlled trials conducted in Japan and in the west. Drug Saf. 35(10), 793–806 (2012).
  • Hoppe C, Rademacher M, Hoffmann JM, Schmidt D, Elger CE. Bodyweight gain under pregabalin therapy in epilepsy: mitigation by counseling patients? Seizure 17(4), 327–332 (2008).
  • Criswell KA, Cook JC, Wojcinski Z et al. Mode of action associated with development of hemangiosarcoma in mice given pregabalin and assessment of human relevance. Toxicol. Sci. 128(1), 57–71 (2012).
  • Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J. Clin. Psychopharmacol. 25(2), 151–158 (2005).
  • Filipetto FA, Zipp CP, Coren JS. Potential for pregabalin abuse or diversion after past drug-seeking behavior. J. Am. Osteopath. Assoc. 110(10), 605–607 (2010).
  • Grosshans M, Mutschler J, Hermann D et al. Pregabalin abuse, dependence, and withdrawal: a case report. Am. J. Psychiatry 167(7), 869 (2010).
  • Schwan S, Sundstrom A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system. Eur. J. Clin. Pharmacol. 66(9), 947–953 (2010).
  • Schifano F, D’Offizi S, Piccione M et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother. Psychosom. 80(2), 118–122 (2011).
  • Gahr M, Freudenmann RW, Hiemke C, Kolle MA, Schonfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: results from a database query. Eur. J. Clin. Pharmacol. 69(6), 1335–1342 (2013).
  • Goodwin RD, Stein DJ. Anxiety disorders and drug dependence: Evidence on sequence and specificity among adults. Psychiatry Clin. Neurosci. 67(3), 167–173 (2013).
  • Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress. Anxiety 25(1), 72–90 (2008).
  • Silva ML, Silva MN, Ines M. A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal. Cost Eff. Resour. Alloc. 11(1), 8 (2013).
  • Vera-Llonch M, Dukes E, Rejas J, Sofrygin O, Mychaskiw M, Oster G. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective. Eur. J. Health Econ. 11(1), 35–44 (2010).
  • De Salas-Cansado M, Olivares JM, Alvarez E, Carrasco JL, Barrueta A, Rejas J. Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain. Clinicoecon. Outcomes Res. 4, 157–168 (2012).
  • De Salas-Cansado M, Alvarez E, Olivares JM, Carrasco JL, Ferro MB, Rejas J. Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain. Soc. Psychiatry Psychiatr. Epidemiol. 48(6), 985–996 (2013).
  • Trivedi MH, Fava M, Wisniewski SR et al. Medication augmentation after the failure of SSRIs for depression. N. Engl. J. Med. 354(12), 1243–1252 (2006).
  • Montgomery S, Chatamra K, Pauer L, Whalen E, Baldinetti F. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br. J. Psychiatry 193(5), 389–394 (2008).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.